NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Virtual Reality Cognitive Stimulation for Alzheimer's
Virtual Reality Cognitive Stimulation for Alzheimer's

NCT07645638

CompletedNA

Sponsor: Universidad de Burgos

Conditions: Alzheimer Disease, Memory Disorders

Interventions: Virtual reality

Countries: Spain

This study aims to evaluate whether immersive virtual reality (VR) can improve cognitive function and memory in patients with Alzheimer's disease. Twenty participants in Burgos, Spain, will engage in VR sessions that recreate scenes from 1960s Burgos, representing environments familiar from the participants' youth. The effects of these VR-based cognitive stimulation sessions will be assessed through pre- and post-intervention evaluations, including behavioral observations, EEG monitoring of brain activity, and standardized neurocognitive tests (Montreal Cognitive Assessment, Clock-Drawing Test, and Verbal Fluency Test).

Eligibility overview

Sex: ALL

Age: 60 Years to 90 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Diagnosed with mild cognitive impairment
* Aged 60 years or older.
* Resident or attending care at the Alzheimer's care center in Burgos.
* Capable of providing informed consent, either directly or through a legally authorized representative.
* Adequate vision and hearing (corrected if necessary) to engage with the VR experience.
* Able to tolerate wearing a VR headset for sessions of approximately 15-30 minutes.

Exclusion Criteria:

* Diagnosis of other neurodegenerative disorders (e.g., Parkinson's disease, Huntington's disease, multiple sclerosis).
* History of severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).
* Severe vision or hearing impairment that cannot be corrected (e.g., legal blindness).
* History of epilepsy, seizure disorders, or other conditions that may be aggravated by VR exposure.
* Active skin conditions or infections that prevent the use of a VR headset or EEG sensors.
* Participation in another interventional clinical trial within the last 30 days.
Locations (1)
  • Burgos, Burgos, Spain